Foghorn Therapeutics Income Statement (2020-2025) | FHTX

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue -0.26M-0.20M0.18M0.25M0.29M0.28M0.04M0.71M3.92M4.49M6.63M4.18M5.31M5.60M17.48M5.77M5.05M6.89M7.81M2.86M5.95M7.56M8.15M
Operating items
Research & Development 11.50M13.63M16.11M16.47M18.73M18.64M20.49M22.46M24.51M25.97M26.93M28.21M29.98M29.25M26.25M24.20M25.53M23.80M24.69M20.51M21.63M21.79M20.00M
Selling, General & Administrative 2.22M1.91M2.56M4.56M4.69M4.90M5.81M6.33M7.22M7.70M7.96M7.86M8.64M8.40M8.31M7.02M7.71M7.33M6.97M6.35M7.24M6.86M6.65M
Other Operating Expenses 2.40M
Operating Expenses 13.72M15.54M18.67M21.03M23.42M23.54M26.30M28.80M31.72M33.68M34.89M36.07M38.63M37.65M34.56M31.23M33.24M33.52M31.66M26.86M28.86M28.65M26.65M
Operating Income -13.72M-15.54M-18.49M-20.78M-23.13M-23.26M-26.26M-28.08M-27.80M-29.19M-28.26M-31.89M-33.32M-32.05M-17.08M-25.46M-28.19M-26.63M-23.85M-24.00M-22.91M-21.10M-18.50M
EBIT -13.72M-15.54M-18.49M-20.78M-23.13M-23.26M-26.26M-28.08M-27.80M-29.19M-28.26M-31.89M-33.32M-32.05M-17.08M-25.46M-28.19M-26.63M-23.85M-24.00M-22.91M-21.10M-18.50M
Non-operating items
Interest & Investment Income 0.23M1.23M1.84M2.38M2.67M2.79M2.75M2.66M2.44M2.87M3.50M3.10M2.69M2.31M2.03M
Other Non Operating Income 0.03M0.01M0.39M0.56M0.63M0.65M0.68M-1.20M0.66M0.65M0.65M0.62M0.72M0.71M0.72M0.68M0.74M0.78M1.24M1.41M1.39M0.85M0.62M
Non Operating Income -0.23M-0.18M0.12M0.02M0.14M0.15M0.18M2.02M0.89M1.88M2.49M3.00M3.39M3.50M3.47M3.34M3.18M3.65M4.73M4.50M4.08M3.16M2.65M
Net income details
EBT -13.98M-15.74M-18.69M-21.10M-23.62M-23.76M-26.76M-28.51M-26.91M-27.31M-25.77M-28.89M-29.93M-28.55M-13.61M-22.12M-25.02M-22.98M-19.12M-19.50M-20.22M-18.79M-16.47M
Tax Provisions 0.56M0.94M0.74M1.99M
Profit After Tax -13.95M-15.72M-18.37M-20.76M-23.00M-23.11M-26.08M-29.12M-26.91M-27.31M-25.77M-28.90M-30.50M-29.49M-14.35M-24.11M-25.02M-22.98M-19.12M-19.50M-18.83M-17.94M-15.85M
Income from Continuing Operations -13.98M-15.74M-18.69M-21.10M-23.62M-23.76M-26.76M-28.51M-26.91M-27.31M-25.77M-28.89M-30.49M-29.49M-14.35M-24.11M-25.02M-22.98M-19.12M-19.50M-20.22M-18.79M-16.47M
Consolidated Net Income -13.98M-15.74M-18.69M-21.10M-23.62M-23.76M-26.76M-28.51M-26.91M-27.31M-25.77M-28.89M-30.49M-29.49M-14.35M-24.11M-25.02M-22.98M-19.12M-19.50M-20.22M-18.79M-16.47M
Income towards Parent Company -13.98M-15.74M-18.69M-21.10M-23.62M-23.76M-26.76M-28.51M-26.91M-27.31M-25.77M-28.89M-30.49M-29.49M-14.35M-24.11M-25.02M-22.98M-19.12M-19.50M-20.22M-18.79M-16.47M
Net Income towards Common Stockholders -13.98M-15.74M-18.69M-21.10M-23.62M-23.76M-26.76M-28.51M-26.91M-27.31M-25.77M-28.89M-30.49M-29.49M-14.35M-24.11M-25.02M-22.98M-19.12M-19.50M-20.22M-18.79M-16.47M
Additional items
EPS (Basic) -2.71-2.90-3.122.53-0.62-0.63-0.71-0.77-0.65-0.66-0.62-0.69-0.73-0.70-0.34-0.57-0.59-0.45-0.31-0.30-0.30-0.28-0.25
EPS (Weighted Average and Diluted) -2.71-3.122.53-0.62-0.63-0.71-0.77-0.65-0.66-0.62-0.69-0.73-0.70-0.34-0.57-0.59-0.45-0.31-0.30-0.30-0.28-0.25
Shares Outstanding (Weighted Average) 35.69M35.69M35.69M35.81M36.82M36.85M36.94M37.09M41.42M41.47M41.64M41.80M41.80M41.82M41.86M42.22M42.57M42.59M55.33M55.59M55.61M55.74M56.53M
Shares Outstanding (Diluted Average) 5.42M5.88M11.05M36.82M36.85M36.97M37.17M41.37M41.52M41.67M41.59M41.81M41.83M42.03M41.97M42.43M51.58M62.60M54.90M62.85M62.98M63.03M
EBITDA -13.95M-15.72M-18.37M-20.77M-22.97M-23.13M-26.08M-29.14M-28.10M-29.31M-27.44M-28.01M-29.37M-29.34M-13.52M-23.04M-24.69M-22.82M-18.42M-19.73M-18.95M-17.99M-15.78M
Interest Expenses 0.26M0.20M0.20M0.32M0.49M0.49M0.50M0.43M